Your browser doesn't support javascript.
loading
ERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells.
Tome-Garcia, Jessica; Li, Dan; Ghazaryan, Seda; Shu, Limin; Wu, Lizhao.
Affiliation
  • Tome-Garcia J; Rutgers New Jersey Medical School-Cancer Center, Newark, New Jersey, United States of America.
  • Li D; Rutgers New Jersey Medical School-Cancer Center, Newark, New Jersey, United States of America.
  • Ghazaryan S; Rutgers New Jersey Medical School-Cancer Center, Newark, New Jersey, United States of America.
  • Shu L; Rutgers New Jersey Medical School-Cancer Center, Newark, New Jersey, United States of America.
  • Wu L; Rutgers New Jersey Medical School-Cancer Center, Newark, New Jersey, United States of America; Department of Microbiology and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey, United States of America.
PLoS One ; 9(6): e99525, 2014.
Article in En | MEDLINE | ID: mdl-24937171
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptor, ErbB-2 / Prostatic Neoplasms, Castration-Resistant Limits: Animals / Humans / Male Language: En Year: 2014 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Receptor, ErbB-2 / Prostatic Neoplasms, Castration-Resistant Limits: Animals / Humans / Male Language: En Year: 2014 Type: Article